Recent Headlines
Clinical Research Organization, Huntington Study Group “Firsts” Continue
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) through its Clinical Research Organization (CRO), HSG Clinical Research, Inc. (HSGCR) continues making groundbreaking progress in the HD world. At their Annual Meeting in November, the... - December 05, 2022 - Huntington Study Group
Paras Biopharmaceuticals Finland Oy is Highly Recommended for Biologics CDMO – Development / Scale-up & Production of Biologics by Innovative USA Biopharma Company
Paras Biopharmaceuticals is pleased to announce that the company has been highly recommended for its Biologics CDMO – development / scale-up and production capabilities. The Paras Biopharmaceuticals Team has successfully completed multiple biologics projects in 2022. - November 29, 2022 - Paras Biopharmaceuticals Finland Oy
Huntington Study Group Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its 29th Annual Meeting in Tampa, FL. This renowned meeting brings together HD thought leaders, scientific experts, industry partners and sponsors, advocacy groups, and... - November 29, 2022 - Huntington Study Group
Marty Rosenberg joins the Board of Scientific Advisors at Microvascular Therapeutics.
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Marty Rosenberg to the MVT Board of Scientific Advisors. Mr. Rosenberg brings a broad experience with the clinical development and global regulatory approval process for... - November 25, 2022 - Microvascular Therapeutics, Inc.
David Lim Joins the Team at Microvascular Therapeutics as Director of Finance
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of David Lim as Director of Finance at MVT. Mr. Lim brings a broad experience with the business development and strategic financing for diagnostic pharmaceuticals across all... - November 25, 2022 - Microvascular Therapeutics, Inc.
Novugen Pharma Became the First Pharmaceutical Company in Malaysia to Receive USFDA Approval for Its Manufacturing Facility
The Company was audited in September 2022 and USFDA issued an Establishment Inspection Report (EIR) in November 2022. Novugen Pharma is the first USFDA approved pharmaceutical manufacturing in Malaysia and the only in Southeast Asia. - November 22, 2022 - Novugen
Introducing MIRAPeel MD, the Only 6-in-1 Clinical-Grade Skincare Platform of Its Kind
Attention Dermatologists, Plastic Surgeons and Med Spa Owners: Meet MIRAPeel MD, the one stop shop for all skin needs, and the first of its kind. Offering 6 treatments in one, MIRAPeel MD is setting a new treatment standard for skin care specialists, medical spas, dermatology and plastic surgery offices. - November 22, 2022 - eMIRAmed
Immunodominant Announces Call for Initial Investment Round as Company Prepares for Phase 2 Study of Oral OTC COVID-19 Drug
Immunodominant Inc., a drug discovery and development company engaged in progressing innovative research from academia to commercialization, today announced its intention to begin an initial financing round of up to $30 million. Immunodominant also announced today that it is scheduling a Phase 2 clinical study after a pre-IND meeting with the FDA for LACTOVID, a novel, oral, over-the-counter drug for the prevention and treatment of COVID-19. - November 20, 2022 - Immunodominant
Microvascular Therapeutics Receives Funds from the National Cancer Institute (NCI) for Its Brain Tumor Program
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute (NCI). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are... - November 18, 2022 - Microvascular Therapeutics, Inc.
Prosel Bioscience Becomes One Cell Foods and Names Dr. Scott Jenkins Its New CEO
One Cell Food, Inc will focus on scaling its proprietary bioreactor design to commercialize developed strains for its first food product by early 2023. As the new CEO, Dr. Scott Jenkins will lead the operation and fundraising efforts. - November 17, 2022 - One Cell Foods, Inc.
Families of World War II Veterans Holds 2022 Fundraising Golf Tournament
Families of World War II Veterans held its annual golf tournament and fundraising event on Monday, October 24, at the award-winning Trinity Forest Golf Club in Dallas, Texas, the former home of the renowned AT&T Byron Nelson tournament. This is the organization’s biggest fundraising event... - November 12, 2022 - Careington
Are You Ready to Get Shroomed?
After a historical win for the war on drugs in Colorado, the state and the nation begins to look at ways to implement Magic Mushroom assisted therapy along with other plant medicine. We look at the facts behind this, and what it means for you. - November 11, 2022 - shroomed
PharmStars Announces Fall 2022 Startup Showcase Event
PharmStars, the pharma-focused accelerator for digital health startups, announces that its Fall 2022 Showcase Event will begin on November 8, 2022. The Showcase is the culmination of a 10-week startup accelerator program. At the Showcase Event, startups will make formal presentations to and meet... - November 08, 2022 - PharmStars
Biomed Industries, Inc. (“Biomed”) Today Announced the Closing of Its Merger with MedAware Systems, Inc., (“MedAware”)
Biomed Industries, Inc. (“Biomed”) today announced the closing of its merger with MedAware Systems, Inc., (“MedAware”), in which all issued and outstanding common shares of capital stock of MedAware will be exchanged for common stock of Biomed at a ratio of 5.33 shares of MedAware for 1 new common share of Biomed. The transaction valued at an aggregate of $20 million, to be paid by 2,259,170 common shares of Biomed. At present, Biomed has approximately 76,354,075 common shares issued. - November 07, 2022 - Biomed Industries, Inc.
Thrivous Launches Vitality Geroprotector Formula 2
Thrivous, the human enhancement company, has released Vitality Geroprotector Formula 2 with Mirtoselect® Blueberry Anthocyanin. Vitality is the advanced geroprotector supplement that Thrivous develops to enhance metabolism and cell function for better aging. Vitality combines geroprotector... - November 07, 2022 - Thrivous
Thaddeus Medical Customizable Cold-Chain iQ-Ler Now Available for Pre-Order
Cold Chain system is designed for storage, transportation and dispensary of temperature-sensitive medical therapeutics to eliminate all spoilage in cold-chain logistics and improve patient outcomes - November 03, 2022 - Thaddeus Medical
DistillerSR Launches New CuratorCR Capabilities to More Dynamically Manage and Reuse Evidence-Based Research
CuratorCR Knowledge Center Provides Alternative to Elsevier’s QUOSA Virtual Library as Its Sunset Date Looms. - October 31, 2022 - DistillerSR
Gallant Announces Hiring of John Klacking, Ph.D. as Chief Business Officer
Furthering its regenerative medicine therapeutics research and development, animal biotech company Gallant welcomes a pioneer in the biotech space. - October 25, 2022 - Gallant
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists. - October 25, 2022 - Huntington Study Group
Minus K Technology Announces Announces Its Seventh U.S. Educational Giveaway of Vibration Isolators to Colleges and Universities
As Minus K celebrates their upcoming 30 years in business, they are giving away $25,000* dollars worth of passive mechanical patented superior performing negative-stiffness low-frequency vibration isolators to colleges in the United States. - October 25, 2022 - Minus K Technology Inc.
Vivisum Partners Publishes Strategic Analysis on the Ulcerative Colitis Marketplace
Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners. Vivisum Partners has just published its... - October 25, 2022 - Vivisum Partners, LLC
New Market Insights on the Best MS Treatment Published by Vivisum Partners
What’s the best MS treatment according to neurologists? The question of how to assess the ideal drug to treat multiple sclerosis is difficult to answer. Neurologists determine which clinical attributes take higher priority for each patient. Vivisum Partners, LLC, a market research firm in... - October 24, 2022 - Vivisum Partners, LLC
ARA Breast Radiologist Goes All Pink to Emphasize Importance of Mammography
It’s Breast Cancer Awareness Month and many are working to bring attention to breast cancer and the importance of screening with mammography. However, Dr. Arthy Saravanan, head of the breast imaging section at ARA Diagnostic Imaging, is going the extra mile, in a bright pink car. Dr. - October 18, 2022 - ARA Diagnostic Imaging
Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. “The HSG... - October 18, 2022 - Huntington Study Group
Kantify and Mcule Harness the Power of Data to Accelerate Drug Discovery
Kantify, using its AI technology for drug discovery and Mcule, with its compound sourcing platform, are collaborating to leverage data for better hit prediction. - October 17, 2022 - Mcule
Thrivous Releases Serenity Nightly Nootropic Formula 3
Thrivous, the human enhancement company, has released Serenity Nightly Nootropic Formula 3 with KSM-66® Ashwagandha. Serenity is the advanced nootropic supplement that Thrivous develops to enhance relaxation, sleep, and next-day focus. Serenity combines nootropic nutrients with the highest... - October 14, 2022 - Thrivous
Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) for over 30 years, together with its Clinical Research Organization (“CRO”), the HSG Clinical Research, Inc., today announces the enrollment of the first participant of its... - October 12, 2022 - Huntington Study Group
Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round
Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Bradbury Asset Management (Hong Kong), Limited. Bradbury provided an initial $10 million tranche for this round in... - October 11, 2022 - Mirror Biologics, Inc.
SYNG Pharmaceuticals Announces Issuance of Its Canadian Patent for Non-Hormonal Therapy for Endometriosis
SYNG Pharmaceuticals Inc. (SYNG), a Kingston, Ontario based women’s health biotech, is pleased to announce that on October 04, 2022, the Canadian Intellectual Property Office granted Canada Patent No. 2,903,608 titled, "Treatment of endometriosis, angiogenesis and/or endometrial lesion growth." - October 09, 2022 - SYNG Pharmaceuticals Inc.
Vivisum Partners' Research Finds New Ulcerative Colitis Drugs Provide Excitement to Gastroenterologists
Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options. Based on a market analysis from Vivisum Partners, a market research and brand... - October 08, 2022 - Vivisum Partners, LLC
Tasly Pharmaceuticals to Exhibit at BioJapan 2022 -- Bio-Pharmaceutical Company to Join with Maryland-Based Organizations at Asia’s Premier Biotechnology Partnering Event
Tasly Pharmaceuticals will exhibit at BioJapan 2022, October 12-14 at PACIFICO Yokohama - October 05, 2022 - Tasly Pharmaceuticals, Inc.
Evidence Partners Rebrands as DistillerSR to Leverage Market Awareness of Its Core Literature Review Platform
The Company Also Bolstered Its Executive Team in Security, Product Management and Operations to Support Accelerating Growth - September 28, 2022 - DistillerSR
New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report
800 Current and Future Clinical Trial Participants Link Satisfaction and Willingness to Participate with Decentralized Strategies - September 21, 2022 - Life Science Strategy Group, LLC
Biomed Industries, Inc. to Acquire MedAware Systems, Inc. to Expand Its Artificial Intelligence Research for Drug Discovery in Alzheimer’s Disease
Biomed Industries, Inc. (“BIOMED” or the “Company”), has entered into a share exchange agreement to acquire all of the issued and outstanding shares of MedAware Systems, Inc. MedAware shares was valued at $1.50 per share and BIOMED’s share was valued at $8.00 per share. The transaction was valued at an aggregate of $18 million, to be paid in the form of 2,259,170 common shares of BIOMED. On the date of the Agreement, BIOMED has approximately 76,354,075 common shares. - September 21, 2022 - Biomed Industries, Inc.
MEDraysintell Publishes the 9th Edition of Its Nuclear Medicine Report & Directory
A set of three volumes (3,500 pages) with a description of 970 products, together with a comprehensive profile of 380 companies active around the world in the radiopharmaceutical industry. - September 16, 2022 - MEDraysintell
Appointments Made to the Sterile Compounding Expert Panel Announced by Pharmacy Stars
The Sterile Compounding Expert Panel (SCXP) was established by Pharmacy Stars on July 7, 2022. Pharmacy Stars executive leadership has appointed key members to serve on SCXP’s panel. They have joined in support of the organization’s mission to strengthen sterile compounding practices in... - September 12, 2022 - Pharmacy Stars, LLC
GENINVO Service Offering Custom Application Development
GENINVO is a leading provider of high-quality, innovative life science tools. GENINVO understand the business challenges of enterprises big and small. Whether you need short-term, focused design support or turnkey product development, GENINVO has the right tools to meet your needs with the help of... - September 07, 2022 - GenInvo, Inc.
AeroGo Awarded 2022-2023 Great Place to Work Certification™
AeroGo is proud to announce that the company has been Certified™ by Great Place to Work®. The prestigious award is based entirely on what current employees say about their experience working at AeroGo. Great Place to Work® is the global authority on workplace culture, employee... - September 01, 2022 - AeroGo, Inc.
Paras Biopharmaceuticals Finland Oy Has Been Identified as One of the "Fastest Growing Companies in the Nordic Biotechnology Therapeutics & Diagnostics Industry"
Paras Biopharmaceuticals is pleased to announce that the company has been identified as one of the Fastest Growing Companies in the Nordic Biotechnology Therapeutics and Diagnostics industry by Plimsoll Publishing UK. - September 01, 2022 - Paras Biopharmaceuticals Finland Oy
CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods
The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022 - Cayman Chemical Company
Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program
The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022 - Cayman Chemical Company
Jillian Altizer Joins AeroGo as Human Resources Manager
Jillian Altizer Joins AeroGo as Human Resources Manager. - August 25, 2022 - AeroGo, Inc.
Pharma CI Conference Returns Next Month: Meet Hundreds of Industry Leaders at the Top Event for 15+ Years
Ready, set, engage! The Pharma CI USA Conference & Exhibition is back in person and ready to deliver the industry-leading experience that has made Pharma CI the gold standard event for more than fifteen years. The much-anticipated return happens this September 21-22 at the Newark Liberty... - August 18, 2022 - Pharma CI Conference
VMRD Begins Manufacturing Key Reagent for Detection of CWD by RT-QuIC
Veterinary Medical Research & Development (VMRD), Pullman, WA, has partnered with CWD Evolution, Fort Collins, CO, to provide state-of-the-art diagnostic reagents for detection of the abnormal prion associated with Chronic Wasting Disease (CWD). The control of CWD requires identification of... - August 09, 2022 - VMRD, Inc.
Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing
The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo
International Panel of Experts Provides Guidance on Key Questions in Risk Assessment of PFAS Chemicals
A new peer-reviewed report by a panel of scientists sheds new light on regulation and management of per- and polyfluoroalkyl substances (PFAS). SciPinion, which objectively engages the global scientific community to analyze the toughest scientific topics, today announced the publication of an... - July 19, 2022 - SciPinion
PharmStars Announces Spring 2022 Accelerator Graduates: 11 Digital Health Startups Have Successfully Completed PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - July 12, 2022 - PharmStars
Pharmacy Stars’ New Sterile Compounding Quality Peer Network Aims to Fill the Role Once Held by the Now Discontinued CriticalPoint Peer Network
Pharmacy Stars to launch the Sterile Compounding Quality Peer Network with the goal of filling the vacated role of CriticalPoint’s Peer Network, an online forum designed to support 503A entities, their regulators, and their certifiers. The CriticalPoint Peer Network has been discontinued as of June 30, 2022, according to the CriticalPoint website. - July 11, 2022 - Pharmacy Stars, LLC
River Valley Relief Names Ryan Kenaga President
River Valley Relief (RVR), a family-owned medical cannabis cultivator located in Fort Smith, Arkansas makes some organizational changes and names new President. - July 08, 2022 - River Valley Relief
Global Cancer Technology Successfully Concludes Glioblastoma Pre-Clinical Animal Studies with Impressive Results
Global Cancer Technology, a San Diego, CA biotechnology company, has successfully completed animal testing with GCT.GLIO.1, a PI3K selective inhibitor that can cross the blood brain barrier and modulate immune cell function. The company will advance the compound to Phase 1 clinical trials as a next step. - July 08, 2022 - Global Cancer Technology